Bendamustine to Treat Follicular Lymphoma

Follicular lymphoma is a type of slow-growing non-Hodgkin lymphoma (NHL). It occurs when abnormal white blood cells (lymphocytes) build up in lymph nodes, forming masses or lumps. While the exact cause is often unknown, most people with follicular lymphoma live for many years.

What is Bendamustine?

Bendamustine is a type of chemotherapy medication used to treat various types of cancer, including follicular lymphoma. It was first approved in the US in 2008, and it belongs to a group of drugs called alkylating agents. These drugs work by damaging the DNA of cancer cells, preventing them from multiplying.

Your medical team might also refer to bendamustine by its commercial names: Bendeka or Treanda.

How Does Bendamustine Work?

Bendamustine is administered through a vein (intravenously) and takes about 30-60 minutes to complete. The frequency of treatment depends on the specific cancer and treatment plan.

Like other chemotherapy drugs, bendamustine can cause side effects. These may include:

• Increased risk of infection: Due to a decrease in white blood cells
• Bleeding or bruising: Caused by a reduction in platelets
• Nausea and vomiting: Anti-nausea medications can help
• Fatigue: Feeling tired
• Digestive issues: Such as sore throat, stomach upset, or rectal discomfort
• Headaches: Over-the-counter pain relievers may help

It's important to discuss potential side effects with your doctor and report any concerns promptly.

Bendamustine and Follicular Lymphoma

Bendamustine, often used in combination with rituximab (a type of immunotherapy), can be an effective treatment for follicular lymphoma. Some studies suggest it may be better tolerated than other standard chemotherapeutic regimens like R-CHOP.

However, it's essential to note that every patient is unique. What works for one person may not work for another. Your doctor will carefully consider your individual situation when recommending a treatment plan.

What's New in Bendamustine Research?

Exciting developments in cancer research are exploring new combinations of bendamustine with other novel therapies. Clinical trials are investigating how bendamustine might work even better when paired with other newer medications. These studies aim to find more effective and tolerable treatment options for patients with follicular lymphoma.

For example, a phase I/II trial is investigating the combination of tazemetostat (Tazverik, IPSEN) with bendamustine in patients diagnosed with follicular lymphoma. This study aims to determine the safety and effectiveness of this combination. Explore other clinical trials recruiting patients with follicular lymphoma with Healthtree's Clinical Trial Finder.

Important Safety Considerations

While bendamustine can be an effective treatment option, it's also associated with certain risks. Recent research highlights the importance of close monitoring for infections, especially in patients receiving long-term treatment with rituximab.

Conclusion

Bendamustine is a chemotherapy medication used to treat follicular lymphoma. While it can be an effective treatment option, it's essential to weigh the potential benefits against the risks. As with any cancer treatment, open communication with your healthcare provider is crucial.

The journey through a cancer diagnosis can be overwhelming. Staying informed about treatment options and advancements is essential. Consider joining our newsletter to receive the latest updates on follicular lymphoma and other related topics.

Subscribe to healthtree newsletter

Sources:

• Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
• MedlinePlus - Bendamustine
• A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma